GSK acquires US-based Sierra Oncology for $1.9bn
In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.

In June this year, Sierra filed a New Drug Application with the US Food and Drug Administration for momelotinib.
At the closing of the deal, Blueprint will get a total of $575m in cash.
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
The latest approval is based on findings from the Phase II ZUMA-5 trial in 122 relapsed or refractory FL patients.
Sutro could be eligible for milestone payments of up to $422.5m for each product candidate.
The latest development is based on findings from the global Phase III OlympiA trial of Lynparza.
Breyanzi’s indication will include people whose LBCL is refractory to initial chemoimmunotherapy or relapse within a year.
The alliance agreement covers preclinical and clinical studies to be undertaken collaboratively in several solid tumours.
Thank you for subscribing to Pharmaceutical Technology